Subtype
Pancreatic Intraductal Papillary Mucinous Neoplasm
CI-CAN-00003571Explore in graph →
Non-malignant7 active trials
Loading cancer entity…
Subtype
CI-CAN-00003571Explore in graph →
Clinical trials
41 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04207944 | The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial) | active not recruiting | Phase 2 | 100 | Duke UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06519097 | Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3) | active not recruiting | Phase 2 | 4 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 13, 2025 | clinicaltrials |
| NCT00482625 |
| Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery |
| terminated |
| Phase 2 |
| 6 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Oct 16, 2014 |
| clinicaltrials |
Data updated 22 days agoSource updated Sep 8, 2026source: clinicaltrials